Menu
Home
GPcardio CVD, CKD & T2D About EPCCS About IPCCS NCD Academy EACH WONCA World 2025
EPCCS
About EPCCS Connected Societies GPcardio About IPCCS
Education
Lipid Management in ... Cardio Renal Update Cardiovascular Updat... The EU Cardiovascula... Cardiovascular Disea... Managing CV risk in ...
Resources
Practice Guidance Meeting reports STRATIFYHF Recent News Video updates WONCA World 2025
Literature
Left Atrial Appendag... 26 Mar. Novel cardiovascular... 26 Mar. Systemic Inflammatio... 24 Mar. Use of Coronary Arte... 16 Mar. 2026 ACC/AHA Guideli... 13 Mar. Off-label underdosin... 12 Mar. Semaglutide promotes... 9 Mar. Effect of baxdrostat... 7 Mar. More Literature

Feb. 5, 2026

Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis

results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial

Mazen Noureddin, Kris V Kowdley, Tatjana Odrljin et al. - The Lancet

This phase 2 trial of efimosfermin alfa (FGF21 analogue) showed favorable tolerability in patients with MASH and F2/F3 fibrosis. The results support further development of metabolic therapies targeting the liver-cardiovascular axis.

Summary

In this phase 2 trial, treatment with efimosfermin once per month was generally well tolerated in participants with biopsy-confirmed MASH and F2 or F3 fibrosis. These results support the further development of efimosfermin for treatment of MASH-related fibrosis.

Source